CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors treatment, such as anti-PD 1 (nivolumab, pembrolizumab, cemiplimab) or anti-PD-L1 ( atezolizumab, durvalumab) or anti-CTLA-4 (ipilimumab), has recently been emphasized in several NSCLC clinical trials.